US President Donald Trump is spearheading a major shake-up of the U.S. pharmaceutical market by urging drugmakers to sell directly to consumers. While the move is framed as an effort to lower prices, it is already sparking controversy because companies tied to Trump’s son, Donald Trump Jr., and Commerce Secretary Howard Lutnick’s family stand to gain financially, the Wall Street Journal reported.

BlinkRx at the center of the plan

BlinkRx, an online prescription delivery firm that added Trump Jr. to its board earlier this year, is playing host to a high-profile pharmaceutical summit in December. The event, co-organized with the investment firm 1789 Capital, will bring top drugmakers together with Trump administration officials, including health and finance leaders. BlinkRx markets itself

See Full Page